Since the introduction of the Human Papilloma Vaccine, HPV, in 2008 for young girls in the UK to immunise them against the virus that causes cervical cancer, there has been a review of the vaccine to look into possible side-effects.
HPV is a very common, mainly sexually transmitted infection among women and girls who indulge in early sexual activity. The vaccine was first launched during the administration offormer President Goodluck Jonathan when about 300 young girls were vaccinated in a pilot project in Nigeria.
The European Medicines Agency, EMA, said it has begun a review of HPV vaccines, looking into possible rare side-effects which are complex regional pain syndrome and a condition where standing up by vaccinated persons causes dizziness and rapid heart report.
Both conditions can occur in non-vaccinated individuals and “it is considered important to further review if the number of cases reported with HPV vaccine is greater than would be expected,” said the EMA.
Based on this review, it will decide whether to recommend changes to product information to better inform patients and healthcare professionals.
While the review is ongoing, there is no change in recommendations for the use of HPV vaccines, the agency noted.
According to the Deputy Director of Vigilance and Risk Management of Medicines at the UK’s drug regulatory body, the MHRA, Dr. Sarah Branch, “More than eight million doses of HPV vaccine have been given in the UK, with close to 90 percent of eligible teenagers vaccinated. With this very high level of vaccine uptake, such reports are to be expected. But the vaccine isn’t necessarily the cause and coincidental illness is a factor.”
The MHRA said it has been notified of about 12 cases of postural orthostatic tachycardia syndrome and 10 cases of complex regional pain syndrome.

READ ALSO  Health ministry tracks 4 major diseases outbreaks